Skip to main content
Clinical Trials/NCT05664958
NCT05664958
Completed
Phase 4

Erector Spinae Plane Block With Liposomal Bupivacaine for Post Cesarean Delivery Analgesia: A Pilot Study

Duke University1 site in 1 country150 target enrollmentApril 17, 2023

Overview

Phase
Phase 4
Intervention
Erector Spinae Plane (ESP) Block
Conditions
Cesarean Section Complications
Sponsor
Duke University
Enrollment
150
Locations
1
Primary Endpoint
Postoperative Oxycodone Consumption 0- 48 Hours After Cesarean Delivery
Status
Completed
Last Updated
last year

Overview

Brief Summary

The purpose of this pilot study is to assess the analgesic efficacy of Erector Spinae Plane block (ESPB) with liposomal bupivacaine in women undergoing cesarean delivery and receiving a postoperative multimodal analgesic regimen as assessed by the dose of rescue postoperative opioids compared to a historical control group of women receiving the same multimodal regimen but with no truncal blocks. This will be a case control study with a prospective and a retrospective component. Women undergoing elective cesarean delivery under spinal or combined spinal epidural anesthesia will be approached to participate in the prospective open label component of the study. Cases will be matched in a 1:4 ratio by age, race, history of prior cesarean delivery, and insurance status with historical controls who received the same multimodal analgesic regimen but no truncal blocks. We plan to enroll 30 subjects for the prospective arm of the study and 120 for the retrospective arm.

Detailed Description

This will be a case control study with a prospective and a retrospective component. Women undergoing elective cesarean delivery under spinal or combined spinal epidural anesthesia will be approached to participate in the prospective open label component of the study. Those women will receive the standard of care intraoperative and postoperative analgesic regimen used at Duke university incorporating 100 mcg intrathecal morphine, intraoperative acetaminophen 975 mg PR and ketorolac 15 mg IV and postoperative scheduled oral acetaminophen 975 mg every 6 hours, scheduled 15 mg IV ketorolac for 3 doses every 6 hours followed by oral ibuprofen 600 mg every 6 hours. At the end of surgery, a bilateral ESPB will be performed under ultrasound guidance using 133 mg liposomal bupivacaine and 20 ml bupivacaine 0.25% per side. Cases will be matched in a 1:4 ratio by age, race, history of prior cesarean delivery, and insurance status with historical controls who received the same multimodal analgesic regimen but no truncal blocks.

Registry
clinicaltrials.gov
Start Date
April 17, 2023
End Date
November 9, 2023
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
Female

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Patients ≥18 years of age with a term pregnancy of 37 to 42 weeks and American Society of Anesthesiologists Physical Status Classification II or III scheduled to undergo elective CD.

Exclusion Criteria

  • ≥3 prior CDs, pre-pregnancy body mass index \>40 kg/m2, planned concurrent surgical procedure other than tubal ligation, chronic pain or chronic opioid therapy, any clinically significant event or condition uncovered during surgery (eg, excessive bleeding, acute sepsis) that might render the patient medically unstable or complicate the patient's postsurgical course, or allergy or contraindication to any component of the multimodal analgesic regimen.

Arms & Interventions

ESP Block

Standard of care analgesic regimen with ESP Block

Intervention: Erector Spinae Plane (ESP) Block

ESP Block

Standard of care analgesic regimen with ESP Block

Intervention: bupivacaine liposome injectable suspension

ESP Block

Standard of care analgesic regimen with ESP Block

Intervention: bupivacaine

Outcomes

Primary Outcomes

Postoperative Oxycodone Consumption 0- 48 Hours After Cesarean Delivery

Time Frame: 0-48 hours after cesarean delivery

Total dose of rescue oxycodone used in mg 0- 48 hours after cesarean delivery

Secondary Outcomes

  • Postoperative Opioid Consumption at 24 Hours(0-24 hours)
  • Time to First Postsurgical Opioid Rescue Medication(0-48 hours)
  • Area Under the Curve (AUC) of Verbal Rating Scale (VRS) Pain Intensity Scores(0-48 hours)
  • Number of Participants With Postoperative Nausea and Vomiting(0-48 hours)
  • Number of Participants With the Need for Rescue Antiemetics(0-48 hours)
  • Number of Participants With Pruritus(0-48 hours)
  • Number of Participants With the Need for Rescue Antipruritics(0-48 hours)
  • Number of Participants Not Receiving Any Rescue Opioids Postoperatively(0-48 hours)

Study Sites (1)

Loading locations...

Similar Trials